Maze Therapeutics, Inc. Logo

Maze Therapeutics, Inc.

Develops small molecule precision medicines based on insights from human genetics.

MAZE | US

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
171 OYSTER POINT BOULEVARD, SUITE 300, 94080 SOUTH SAN FRANCISCO

Description

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company that harnesses insights from human genetics to develop novel, small molecule precision medicines. The company utilizes its proprietary Compass platform, which leverages variant functionalization, to identify and validate new therapeutic targets. Maze's strategy focuses on designing medicines that imitate the effects of rare, naturally occurring, protective genetic variants to address common diseases with significant unmet medical needs. Its pipeline is focused on advancing treatments for renal and cardio-metabolic indications, with a lead program targeting APOL1-mediated kidney disease (AMKD).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Maze Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Maze Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Maze Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.